Apararenone

阿帕利酮

Report date: 2024/04/01 20:04:33
NME

Base Information

Drug NameApararenone
Drug Alias NameMT-3995
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMineralocorticoid receptor antagonists
TargetsMineralocorticoid receptor
Therapy Area/IndicationsDiabetic NephropathiesMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaSlovakia +[10] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMitsubishi Tanabe Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMitsubishi Tanabe Pharma Corp
Active IndicationsN/A
Inactive IndicationsDiabetic NephropathiesMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A